Anthera Pharmaceuticals, Inc. (ANTH)
Stock Price:
$0.0370 USD
-0.0060 (-13.95%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
968,623 |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-23.39M |
| Shares Out |
26.18M |
| EPS (ttm) |
-1.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$0.0370 |
| Previous Close |
$0.0430 |
| Change ($) |
-0.0060 |
| Change (%) |
-13.95% |
| Day's Open |
0.0350 |
| Day's Range |
0.0340 - 0.0370 |
| Day's Volume |
55,063 |
| 52-Week Range |
0.0161 - 0.0750 |
More Stats
| Market Cap |
968,623 |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
26.18M |
| Float |
26.13M |
| EPS (basic) |
-1.71 |
| EPS (diluted) |
-1.76 |
| FCF / Share |
-1.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.02M |
| Short Ratio |
2.09 |
| Short % of Float |
10.45% |
| Beta |
2.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
0.11 |
| Revenue |
n/a |
| Operating Income |
-36.80M |
| Net Income |
-23.39M |
| Free Cash Flow |
-31.59M |
| Net Cash |
8.09M |
| Net Cash / Share |
0.31 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-141.96% |
| ROE |
-568.85% |
| ROIC |
1,210.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.00
Current: $0.0370
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|
| Revenue | - | 0.15 | 3.19 | - | - | - | - | - | - | - |
| Revenue Growth | - | -95.45% | - | - | - | - | - | - | - | - |
| Gross Profit | - | 0.15 | 3.19 | - | - | - | - | - | - | - |
| Operating Income | -36.43 | -57.18 | -35.24 | -28.46 | -28.25 | -55.93 | -93.14 | -35.76 | -11.84 | -13.86 |
| Net Income | -26.87 | -55.52 | -35.22 | -29.60 | -30.86 | -45.33 | -99.07 | -40.41 | -12.20 | -18.10 |
| Shares Outstanding | 10.28 | 5.16 | 4.45 | 2.72 | 2.28 | 0.90 | 0.58 | 0.36 | 0.02 | 0.02 |
| Earnings Per Share | -2.86 | -12.87 | -7.91 | -10.88 | -13.52 | -50.16 | -169.44 | -112.64 | -515.84 | -862.08 |
| Operating Cash Flow | -36.90 | -48.92 | -30.91 | -25.60 | -31.91 | -73.64 | -73.07 | -27.78 | -17.17 | -17.12 |
| Capital Expenditures | - | -0.77 | -0.08 | - | -0.02 | -0.21 | -1.35 | -0.02 | - | -0.01 |
| Free Cash Flow | -36.90 | -49.69 | -30.99 | -25.60 | -31.93 | -73.84 | -74.41 | -27.80 | -17.18 | -17.13 |
| Cash & Equivalents | 2.20 | 20.84 | 46.95 | 2.64 | 35.95 | 24.75 | 67.37 | 63.38 | 3.80 | 7.94 |
| Total Debt | - | - | - | - | 17.88 | 20.55 | 24.33 | - | 13.13 | - |
| Net Cash / Debt | 2.20 | 20.84 | 46.95 | 2.64 | 18.07 | 4.20 | 43.04 | 63.38 | -9.33 | 7.94 |
| Assets | 3.67 | 23.47 | 48.13 | 3.49 | 37.42 | 26.45 | 69.49 | 65.26 | 5.89 | 8.03 |
| Liabilities | 9.17 | 10.62 | 8.47 | 5.75 | 22.66 | 29.97 | 50.41 | 8.01 | 18.17 | 8.49 |
| Book Value | -5.50 | 12.47 | 39.66 | -2.26 | 14.76 | -3.53 | 19.08 | 57.26 | -12.28 | -0.46 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Anthera Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
21 |
Stock Information
| Ticker Symbol |
ANTH |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: ANTH |
| IPO Date |
March 1, 2010 |
Description
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.